Ipravent

Ipravent: an effective bronchodilator

Ipravent (international name - Ipratropium bromide) is a bronchodilator that is used to treat chronic obstructive bronchitis, bronchial asthma, sputum hyperproduction and bronchial obstruction due to colds. The drug is an m-anticholinergic blocker and is available in the form of a powder for inhalation in capsules of 40 mcg/dose.

Ipravent is manufactured by Cipla Ltd. in India. In addition, the drug has several synonyms, such as Arutropid, Atrovent, Atrovent N, Vagos and Itrop.

The active substance of Ipravent is Ipratropium bromide. The drug blocks muscarinic receptors, which leads to dilation of the bronchi and a decrease in sputum secretion.

Like any other medication, Ipravent has its contraindications and side effects. Contraindication is hypersensitivity to Ipratropium bromide. Undesirable effects include cough, very rarely - paradoxical bronchospasm, allergic reactions (rash, urticaria), dry mouth, headache, nausea and disturbance of accommodation (if it gets into the eyes).

The interaction of Ipravent with other drugs can lead to an increase in the bronchodilator effect of beta-agonists and xanthine derivatives, as well as an increase in the anticholinergic effect of other drugs.

In case of overdose with Ipravent, minor manifestations of systemic anticholinergic effects may occur, such as dry mouth, impaired accommodation and increased heart rate. Treatment is carried out symptomatically.

It should also be noted that Ipravent has some special instructions. The drug is not recommended for angle-closure glaucoma, urinary disorders due to prostate hypertrophy, breastfeeding and pregnancy.

Ipravent is an effective bronchodilator that helps improve breathing in diseases of the respiratory system. However, before using it, you should consult your doctor and read the instructions for use.